Literature DB >> 25288052

Bridging the gap: exploring the barriers to using economic evidence in healthcare decision making and strategies for improving uptake.

Gregory Merlo1, Katie Page, Julie Ratcliffe, Kate Halton, Nicholas Graves.   

Abstract

Evidence from economic evaluations is often not used to inform healthcare policy despite being well regarded by policy makers and physicians. This article employs the accessibility and acceptability framework to review the barriers to using evidence from economic evaluation in healthcare policy and the strategies used to overcome these barriers. Economic evaluations are often inaccessible to policymakers due to the absence of relevant economic evaluations, the time and cost required to conduct and interpret economic evaluations, and lack of expertise to evaluate quality and interpret results. Consistently reported factors that limit the translation of findings from economic evaluations into healthcare policy include poor quality of research informing economic evaluations, assumptions used in economic modelling, conflicts of interest, difficulties in transferring resources between sectors, negative attitudes to healthcare rationing, and the absence of equity considerations. Strategies to overcome these barriers have been suggested in the literature, including training, structured abstract databases, rapid evaluation, reporting checklists for journals, and considering factors other than cost effectiveness in economic evaluations, such as equity or budget impact. The factors that prevent or encourage decision makers to use evidence from economic evaluations have been identified, but the relative importance of these factors to decision makers is uncertain.

Mesh:

Year:  2015        PMID: 25288052     DOI: 10.1007/s40258-014-0132-7

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  19 in total

1.  A cross-sectional study on the determinants of health-related quality of life in the Philippines using the EQ-5D-5L.

Authors:  Kent Jason G Cheng; Adovich S Rivera; Red Thaddeus D P Miguel; Hilton Y Lam
Journal:  Qual Life Res       Date:  2021-03-07       Impact factor: 4.147

Review 2.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 3.  Open science at the science-policy interface: bringing in the evidence?

Authors:  Stefan Reichmann; Bernhard Wieser
Journal:  Health Res Policy Syst       Date:  2022-06-20

4.  The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.

Authors:  Yot Teerawattananon; Sripen Tantivess; Inthira Yamabhai; Nattha Tritasavit; Damian G Walker; Joshua T Cohen; Peter J Neumann
Journal:  Health Res Policy Syst       Date:  2016-12-03

Review 5.  Evidence use in decision-making on introducing innovations: a systematic scoping review with stakeholder feedback.

Authors:  Simon Turner; Danielle D'Lima; Emma Hudson; Stephen Morris; Jessica Sheringham; Nick Swart; Naomi J Fulop
Journal:  Implement Sci       Date:  2017-12-04       Impact factor: 7.327

6.  Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.

Authors:  Nikki McCaffrey; Billingsley Kaambwa; David C Currow; Julie Ratcliffe
Journal:  Health Qual Life Outcomes       Date:  2016-09-20       Impact factor: 3.186

7.  A systematic review and critical analysis of cost-effectiveness studies for coronary artery disease treatment.

Authors:  Victoria McCreanor; Nicholas Graves; Adrian G Barnett; Will Parsonage; Gregory Merlo
Journal:  F1000Res       Date:  2018-01-17

8.  Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review.

Authors:  Stuart J Wright; William G Newman; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2019-08       Impact factor: 4.981

9.  A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.

Authors:  Hedwig M Blommestein; Margreet G Franken; Carin A Uyl-de Groot
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

10.  Scepticaemia: The impact on the health system and patients of delaying new treatments with uncertain evidence; a case study of the sepsis bundle.

Authors:  Robin Blythe; David Cook; Nicholas Graves
Journal:  F1000Res       Date:  2018-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.